AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals

AdvaMed President Steve Ubl aims to have FDA meeting a 180-day review deadline for expedited PMAs in the next three to five years and to revamp Japan's reimbursement system in the next two years